Acorda Announces Positive Phase 3 Clinical Trial Results for CVT-301

(February 9, 2017) - Acorda Therapeutics, Inc. today announced Phase 3 clinical data of CVT-301, showing a statistically significant improvement in motor function in people with Parkinson’s disease experiencing OFF periods. CVT-301 is an investigational, inhalable formulation of levodopa (L-dopa). It is being studied as a treatment for OFF periods in people with Parkinson’s disease taking an oral carbidopa/ levodopa regimen. Read more